An observational study in IPF, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
The goal of this observational study is to identify the demographic and clinical characteristics associated with the development of diarrheal adverse events in a Caucasian population with IPF undergoing treatment with nintedanib. Additionally this study aims to evaluate the different therapeutic strategies for dose reduction of nintedanib and assess the effectiveness of these strategies in reducing the occurrence of diarrhea.
The study population consists of patients treated with Nintedanib for IPF who are followed at the Interstitial Lung Disease Outpatient Clinic of the Pneumology and Respiratory Intensive Care Unit at the IRCCS Azienda Ospedaliero-Universitaria of Bologna, Policlinico di Sant'Orsola, and who have received the treatment for at least 12 consecutive months.
At the first available visit (which will be conducted according to the routine follow-up schedule), informed consent for partecipation in the study will be obtained. Following the signing of the informed consent, the data relevant to the protocol will be collected retrospectively, concerning the visit at which nintedanib therapy was initiated and the follow-up visits conducted at 6 and 12 months from the start of the antifibrotic therapy, as per clinical practice.
IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 493 studies on the registry; 273 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients treated with Nintedanib for IPF who are seen at the Interstitial Lung Disease Outpatient Clinic of the Pneumology and Respiratory Intensive Care Unit at the IRCCS Azienda Ospedaliero-Universitaria of Bologna, Policlinico di Sant'Orsola, and who have received the treatment for at least 12 consecutive months.
Exclusion Criteria:
Identification of the demographic and clinical characteristics associated with the development of diarrheal adverse events in a Caucasian population with IPF undergoing treatment with nintedanib
Presence and intensity of diarrheal adverse events defined according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, which defines diarrhea as 'frequent and watery bowel movements' and classifies it into the following grades: Grade 1 = Increase in the number of daily bowel movements \< 4 compared to baseline. Grade 2 = Increase in the number of daily bowel movements from 4-6 compared to baseline. Grade 3 = Increase in the number of daily bowel movements \> 7 compared to baseline. Grade 4 = Requires urgent intervention, life-threatening. Grade 5 = Death
Time frame: 18 months
Identification of the functional parameters associated with the temporary dose reduction of nintedanib
Temporary dose reduction of nintedanib
Time frame: 18 months
Evaluation of the proportion of patients requiring a permanent dose reduction of nintedanib (100 mg twice daily) or discontinuation of the drug, and comparison of their characteristics with those patients who did not require therapy modifications.
Permanent reduction or discontinuation of nintedanib. Dose reduction of nintedanib is defined as the transition from the 'full' dose-equivalent to taking one 150 mg capsule twice daily-to the 'reduced' dose-equivalent to taking one 100 mg capsule twice daily. 'Reduction' and 'discontinuation' of nintedanib are considered two distinct outcomes.
Time frame: 18 months
Assessment of the effectiveness of different nintedanib dose reduction strategies in reducing diarrheal symptoms
Effectiveness of the dose reduction strategy, defined as a decrease of at least 1 grade on the CTCAE scale.
Time frame: 18 months
Calculation of the incidence of diarrheal adverse events in a Caucasian population of patients with IPF undergoing antifibrotic treatment with nintedanib during the first year of therapy
Number of diarrheal adverse events.
Time frame: 18 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna